Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure

Table 1 Serial measurements before, during and after treatment with rituximab

	time 0*	time 1**	time 2***	time 3****	time 4*****	time 5******
Antibodies	Jo-1	130	165	160	161	145
SSA	114	110	105	103	100	100
PaO2, mmHg	74	68	73	85	89	86
PaCO2, mmHg	34	30	32	32	35	35
DL_CO, % pred.	80	22	31	35	42	52
Krogh index	80	54,1	67	57	63	65
FVC, % pred.	98	45	46	90	98	99
FEV₁, % pred.	90	50	52	80	90	90
6MWT, m	600	75	150	450	500	500
sPAP, mm Hg	35	35	35	33	33	32

* Before treatment with rituximab. ** 1^st course of rituximab administration. *** Interval between 1^st and 2^nd course of therapy with rituximab. **** 2^nd course of rituximab administration. ***** After 2^nd course of therapy with rituximab. ****** Final medical examination.
Definitions of abbreviations: 6MWT, 6-minute walking test; DL_CO, diffusing lung capacity for carbon monoxide; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; PaCO₂, partial pressure of arterial carbon dioxide; PaO₂, partial pressure of arterial oxygen; sPAP, systolic pulmonary artery pressure.

ISSN: 2049-6958